Deep Genomics vs Predible Health

Neither company has publicly disclosed a valuation, making a definitive size comparison difficult. Deep Genomics employs 100-500 people, while Predible Health has 10-50 employees.

Deep Genomics has raised more in total funding at $180M, compared to Predible Health's $5M — a gap of $175M.

Deep Genomics holds the higher Awaira Score at 68/100, compared to Predible Health's 50/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 18-point gap that reflects meaningful differences in scale or traction.

Deep Genomics was founded by Brendan Frey in 2015. Predible Health was founded by Sanjoy Paul in 2017. Visit each company's profile on Awaira for a full founder biography.

Deep Genomics: Deep Genomics applies deep learning to genetic medicine discovery, using AI models trained on genomic sequence data to predict the functional consequences of genetic variants, identify RNA splicing defects that underlie genetic diseases, and generate novel therapeutic candidates including antisense oligonucleotides and small molecules that correct disease-causing genetic variants. The Toronto company was founded by Brendan Frey, a University of Toronto machine learning professor who collaborated with Geoffrey Hinton on deep learning research.\n\nThe company raised approximately $180 million in venture funding from investors including True Ventures, AlleyCorp, and GV (Google Ventures). Deep Genomics has built an AI drug discovery platform called the AI Workbench that integrates genomic data, disease biology, and AI prediction across the therapeutic discovery pipeline, and has entered a strategic alliance with Agenus to develop cancer treatments using its AI-designed oligonucleotide candidates.\n\nDeep Genomics competes in the AI genetic medicine space against Recursion Pharmaceuticals, Insitro, Exscientia, and gene therapy companies building computational biology capabilities. Its specific focus on RNA biology and oligonucleotide therapeutics, which represent a growing class of approved genetic medicines, differentiates it from platforms focused on small molecule drug discovery or cell therapy. The Toronto University of Toronto AI ecosystem, including connections to the Vector Institute and the Hinton research lineage, provides research credibility and talent access that distinguishes Canadian AI drug discovery from international competitors. Predible Health: Predible Health develops AI software for radiology and medical imaging analysis, with a focus on automated CT scan interpretation for lung nodule detection, COVID-19 assessment, and liver segmentation. The platform integrates with radiology information systems and PACS to provide AI-assisted second reads and quantitative measurements that reduce reporting time and flag critical findings for urgent review.\n\nThe company raised approximately $5M in Series A funding and has established clinical partnerships with hospital networks and diagnostic imaging centers across India. Predible Health received significant validation through its COVID-19 CT analysis tool, which was deployed during the pandemic to help overwhelmed radiology departments manage surge volumes.\n\nRadiology AI represents one of the most commercially mature segments of medical AI globally, with clear clinical workflows, measurable radiologist productivity benefits, and established reimbursement pathways emerging in developed markets. Predible Health's India-focused deployments position it as a domestic alternative to global radiology AI companies, with the advantage of deep integration knowledge in Indian hospital IT environments.

Deep Genomics was founded first in 2015, giving it 2 years of additional market experience. Predible Health was founded later in 2017. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Deep Genomics has approximately 100-500 employees, while Predible Health has approximately 10-50. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Deep Genomics and Predible Health are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.